Cabazitaxel

Form: Injection

Strength: 60 mg/1.5 mL

Reference Brands: Jevtana®(US & EU)

Category: Oncology Cancer Care

Cabazitaxel, a next-generation taxane chemotherapy agent, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with docetaxel. Marketed under the brand Jevtana® in the US and EU, it is available as a 60 mg/1.5 mL injectable concentrate, requiring dilution before intravenous infusion. Cabazitaxel inhibits microtubule depolymerization, disrupting cancer cell mitosis. Manufactured under strict GMP standards, Cabazitaxel is a key product for B2B pharma partners focused on oncology and urology segments. It presents reliable commercial opportunities in highly regulated markets across Europe and North America.